In contrast to AI-driven drug discovery companies like Xaira, Recursion, or DeepMind spinout Isomorphic Labs, which focus on ...

An international team led by Einstein Professor Cecilia Clementi in the Department of Physics at Freie Universität Berlin ...

The company has integrated the AI model into its internal discovery pipeline and aims to use it in collaborative drug discovery programs.

Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of Parkinson's disease and a way to modify it, paving the way for future ...

MiniMax-M1 presents a flexible option for organizations looking to experiment with or scale up advanced AI capabilities while managing costs.

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. Quiver AI Summary MIT and Recursion have released Boltz-2 ...

Microsoft Research has introduced BioEmu-1, a deep-learning model designed to predict the range of structural conformations that proteins can adopt. Unlike traditional methods that provide a ...

Wittenberg purchased the model from A. A. Barker, an employee of Cambridge University Engineering Laboratories, who fabricated the models for sale to interested scientists starting in May 1966 under ...

Eli Lilly last week terminated a Phase II trial of its investigational relaxin analog volenrelaxin in chronic kidney disease, according to an update to the study’s clinicaltrials.gov webpage. Lilly is ...

The model was trained on examples of protein sequences from many species, as well as information on which proteins tend to interact with one another.